Efficacy and safety of tocilizumab in the treatment of acute active antibody-mediated rejection in kidney transplant recipients

Authors

April A. Pottebaum, Barnes Jewish Hospital
Karthikeyan Venkatachalam, Washington University School of Medicine in St. Louis
Chang Liu, Washington University School of Medicine in St. Louis
Daniel C. Brennan, Johns Hopkins University
Haris Murad, Washington University School of Medicine in St. Louis
Andrew F. Malone, Washington University School of Medicine in St. Louis
Tarek Alhamad, Washington University School of Medicine in St. Louis

Journal

Transplantation Direct

Publication Date

2020

Volume

6

Issue

4

First Page

e543

Document Type

Open Access Publication

DOI

10.1097/TXD.0000000000000988

Rights and Permissions

Pottebaum, A. A., Venkatachalam, K., Liu, C., Brennan, D. C., Murad, H., Malone, A. F., & Alhamad, T. (2020). Efficacy and safety of tocilizumab in the treatment of acute active antibody-mediated rejection in kidney transplant recipients. Transplantation Direct, doi:10.1097/TXD.0000000000000988 Copyright © 2020 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Recommended Citation

Pottebaum, April A.; Venkatachalam, Karthikeyan; Liu, Chang; Brennan, Daniel C.; Murad, Haris; Malone, Andrew F.; and Alhamad, Tarek, "Efficacy and safety of tocilizumab in the treatment of acute active antibody-mediated rejection in kidney transplant recipients." Transplantation Direct. 6, 4. e543 (2020).
https://digitalcommons.wustl.edu/open_access_pubs/9298